Abstract
Advances in our understanding of asthma pathogenesis and delineation of the human genome project are yielding novel candidate targets for therapeutic intervention. In parallel with target identification, the past decade has produced novel approaches to normalizing expression genes that are upregulated in disease processes. Single-stranded antisense oligonucleotides and double-stranded short-interfering RNA molecules, which specifically mark target transcripts for degradation, are being investigated for their ability to modulate disease processes. In both cases, the targets are RNA transcripts, and not protein; therefore, all types of molecular gene products can be inhibited, including historically undrugable species such as transcription factors and phosphatases. Various RNA interference strategies have been successfully tested in vitro and in animal models of disease, and data is beginning to accumulate from human clinical trials.
EPI-2010, a 21-mer phosphorothioate against the adenosine A1 receptor promoter region, has completed preclinical pharmacology testing and its initial clinical trials. The rationale for EPI-2010 is that overactivity of the adenosine signaling pathway in asthmatic lungs contributes to airway inflammation and hyperresponsiveness. Phase I/IIa clinical trials have shown EPI-2010 to be safe and well-tolerated, with modest indications of efficacy in patients with mild asthma.
Similar content being viewed by others
References
Sears, M.R. (1995), J Invest Allergol Clin Immunol 5, 66–72.
http://www.aafa.org. Accessed on Oct. 28, 2004.
Zimmermann, N., Moulton, E.A., Aronow, B.J., et al. (2002), J Allergy Clin Immunol 109(1 suppl), S296,905.
Dove, A. (2002), Nature Biotech 20, 121–124.
Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., and Mello, C.C. (1998), Nature 391(6669), 806–811.
Eric, G. (2001), Current Biology 11, R772-R775.
Nyce, J.W., and Metzger, W.J. (1997), Nature 385(6618), 721–725. Erratum in: (1997) Nature 390(6658), 424.
Kandimalla, E.R., Yu, D., and Agrawal, S. (2002), Curr Opin Mol Ther 4(2), 122–129.
Karol, M.H. (1994), Eur Respir J 7(3), 555–568.
Zou, J., Young, S., Zhu, F., et al. (2002), Genome Biol. 3(5), research0020. Epub 2002 Apr 11.
Agrawal, S. (1999), Biochim Biophys Acta 1489(1), 53–68.
Levin, A.A. (1999), Biochim Biophys Acta 1489(1), 69–84.
Cho-Chung, Y.S. (2002), Curr Opin Investig Drugs 3(6), 934–939.
Tamm, I., Dorken, B., and Hartmann, G. (2001), Lancet 358(9280), 489–497.
de Smet, M.D., Meenken, C.J., and van den Horn, G.J. (1999), Ocul. Immunol. Inflamm. 7, 189–198.
Ali, S., Leonard, S.A., Kukoly, C.A., et al. (2001), Am J Respir Crit Care Med 163, 989–993.
Nicklin, P.L., Bayley, D., Giddings, J., et al. (1998), Pharm Res 4, 583–591.
Agrawal, S. (1999), Biochim Biophys Acta 1489, 53–68.
Wang, H., Cai, Q., Zeng, X., Yu, D., et al. (1999), Proc Natl Acad Sci USA 96, 13,989–13,994.
Crooke, S.T. (1999), Antisense Nucleic Acid Drug Dev 8, 115–122.
Branch, A.D. (1996), Hepatology 24, 1517–1529.
Coulson, J.M., Poyner, D.R., Chabtry, A., et al. (1996), Mol Pharmacol 50, 314–325.
Dapic, V., Bates, P.J., Trent, J.O., et al. (2002), Biochemistry 41(11), 3676–3685.
Finotto, S., De Sanctis, G.T., Lehr, H.A., et al. (2001), J Exp Med 193(11), 1247–1260.
Finotto, S., Buerke, M., Lingnau, K., et al. (2001), J Allergy Clin Immunol 107(2), 279–286.
Stenton, G.R., Kim, M.K., Noharo, O., et al. (2000), J Immunol 164(10), 5532.
Stenton, G.R., Ulanova, M., Dery, R.E., et al. (2002), J Immunol 169(2), 1028–1036.
Allakhverdi, Z., Allam, M., and Renzi, P.M. (2002), Am J Respir Crit Care Med 165, 1015–1021.
Nakanishi, A., Morita, S., Iwashita, H., et al. (2001), Proc Natl Acad Sci USA 98(9), 5175–5180.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ball, H.A., Van Scott, M.R. & Robinson, C.B. Sense and antisense. Clinic Rev Allerg Immunol 27, 207–217 (2004). https://doi.org/10.1385/CRIAI:27:3:207
Issue Date:
DOI: https://doi.org/10.1385/CRIAI:27:3:207